Renascience

Renascience Cash Flow per Share

The Operating Cash Flow per Share of Renascience (4889.T) as of Nov 19, 2026 is -21.14 JPY. In the previous year, Operating Cash Flow per Share was -13.81 JPY — a change of 53.09% (lower).

Cash Flow per Share

-21.14JPY

YoY

53.09%

Last updated:

Operating Cash Flow per Share of Renascience is 2026 -21.14 JPY. Operating Cash Flow per Share of Renascience was 2025 -13.81 JPY. It decreases by 53.09% lower compared to the previous year.

The Renascience Cash Flow per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Flow per Share
Date
Cash Flow per Share
Jan 1, 2020
-12.94 JPY
Jan 1, 2021
-6.48 JPY
Jan 1, 2022
-18.13 JPY
Jan 1, 2023
-22.39 JPY
Jan 1, 2024
-18.13 JPY
Jan 1, 2025
-13.81 JPY
Jan 1, 2026
-21.14 JPY
The Renascience Cash Flow per Share history
YEARCash Flow per ShareYoY
-21.14JPY+53.09%
-13.81JPY-23.84%
-18.13JPY-19.01%
-22.39JPY+23.49%
-18.13JPY+179.88%
-6.48JPY-49.94%
-12.94JPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Renascience Stock analysis

What does Renascience do? Renascience, Inc. develops and sells pharmaceuticals, focusing on drugs for four non-infectious aging-related diseases: cancer, diabetes, respiratory diseases, and cardiovascular diseases. The company collaborates with physicians in research and development of pharmaceuticals, medical devices, and AI solutions for medical problems. Its products target aging-related health issues, including women's and children's diseases and solutions for COVID-19 infection. The firm's revenue comes from the sale of developed pharmaceuticals, medical devices, and AI solutions. Physicians and medical institutions are key buyers of its products, as the company's R&D is conducted in collaboration with them. The primary market segments are aging populations suffering from chronic conditions and healthcare providers seeking innovative medical solutions. Renascience, Inc. operates with a small team of three full-time employees, emphasizing focused R&D on specific medical challenges. Its business model centers on developing targeted therapies for high-impact diseases, leveraging partnerships with physicians to address unmet medical needs in aging-related health conditions. Renascience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Renascience stock

Operating Cash Flow per Share of Renascience is -21.14 JPY in 2026.

Operating Cash Flow per Share of Renascience changed from -13.81 JPY to -21.14 JPY, representing a 53.09% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow per Share Renascience since 2006 – with annual values, charts, and detailed analysis.

Operating cash flow per share measures the operating cash generated per outstanding share.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Renascience

All Key Metrics — Renascience